Chronic DTH in human GA
Chronic DTH in human GA
批准号:
6659330
负责人:
JORDAN S POBER
金额:
$17.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-01 至 2003-08-31
关键词:
SCID mouse arteriosclerosis artery blood vessel transplantation cell differentiation cell sorting delayed hypersensitivity dendritic cells helper T lymphocyte histopathology human subject human tissue immunocytochemistry immunofluorescence technique interferon gamma isoantigen tissue /cell culture transplant rejection vascular endothelium xenotransplantation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Chronic DTH in Human Graft Arteriosclerosis. Graft arteriosclerosis (GA) is caused by a host anti-graft immune response that reduces allograft perfusion through a combination of intimal hyperplasia, pathological vascular remodeling and abnormal vasoregulation. Resultant ischemia produces end organ failure. GA is the major cause of late cardiac allograft loss (chronic rejection). The immunopathogenesis of GA is unknown. Our original immunocytochemical studies pointed to chronic delayed type hypersensitivity (DTH) as the primary mechanism. Based on our findings, we hypothesized that alloreactive, non-cytolytic host T cells within the arterial intima directly respond to alloantigens on graft endothelial cells (EC) by secreting cytokines (e.g. IFN-gamma) that doth directly and indirectly, through activation of macrophage cytokine secretion, act on EC and vascular smooth muscle cells (VSMC) to cause the structural and functional changes that constitute GA. In this project we will ask if human EC can directly stimulate alloreactive CD4+ T cells to differentiate into effector cells that mediate DTH (known as TH1 cells); if they can recruit already differentiate TH1 cells to enter into the intima; if they can activate intimal TH1 cells to secrete IFN-gamma, and if these processes are promoted by EC injury or by EC activation with inflammatory cytokines (e.g., TNF or IL-12). We will also ask if graft EC can indirectly activate or promote the differentiation of TH1 cells (e.g., TNF or IL-12). We will also ask if graft EC can indirectly activate or promote the differentiation of TH1 cells (e.g. via dendritic cells). These experiments will use both cell culture systems (aim 1) and intact human arteries, either in organ culture or after xenotransplantation into SCID/beige mice (aim 2). We will use our intact artery culture and xenotransplant models to determine if alloreactive TH1 cells can produce structural and functional changes in the artery wall that are characteristics of GA (aim 3). We will use standard morphological approaches (e.g., histopathology, immunofluorescence/immunocytochemistry,. In situ hybridization) and supplement these methods with laser capture microscopy/reverse transcription- to analyze these experimental tissues. To validate our models, we will compare our experimental vessels with patient-derived GA specimens using these sample approaches as well as by using these same approaches as well as by using molecular expression profiling with peptide phage display, proteomics and functional genomics (aim 4). The chronic DTH hypothesis to be tested ION Project 1 is central to this PPG application and fits thematically well with the investigations of IFN-gamma actions on vascular cells proposed in Project 2. Project 1 also serves as a basis for the proposed imaging of GA pathophysiology proposed in Project 3. The experiments of Project 1 use all four scientific cores.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Allograft Endothelium
-
批准号:10783379
-
项目类别:
-
资助金额:$41.83万
-
财政年份:2023
-
负责人:JORDAN S POBER
-
依托单位:
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts
-
批准号:10353416
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2021
-
负责人:JORDAN S POBER
-
依托单位:
Assessment of immunogenicity and antigenicity of different human cell types in natural and 3D-printed allografts
-
批准号:10194232
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2021
-
负责人:JORDAN S POBER
-
依托单位:
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium
-
批准号:10197784
-
项目类别:
-
资助金额:$48.94万
-
财政年份:2017
-
负责人:JORDAN S POBER
-
依托单位:
Ex Vivo Nanoparticle Drug Delivery Targeted to Human Renal Allograft Endothelium
-
批准号:10155842
-
项目类别:
-
资助金额:$2.94万
-
财政年份:2017
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:9516109
-
项目类别:
-
资助金额:$37.24万
-
财政年份:2017
-
负责人:JORDAN S POBER
-
依托单位:
Targeting Nanoparticles for Drug Delivery to Renal Graft Endothelium during Ex Vivo Normothermic Perfusion
-
批准号:9164300
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2016
-
负责人:JORDAN S POBER
-
依托单位:
Bioengineered siRNA/Nanoparticles to Prevent Human Transplant Rejection
-
批准号:8693080
-
项目类别:
-
资助金额:$29.1万
-
财政年份:2013
-
负责人:JORDAN S POBER
-
依托单位:
Spatiotemporal Delivery of miRNA Anatgomir for Promoting Vascular Self-Assembly
-
批准号:8322816
-
项目类别:
-
资助金额:$24.91万
-
财政年份:2011
-
负责人:JORDAN S POBER
-
依托单位:
Controlled Spatiotemporal Delivery of miRNA Anatgomir for Promoting Vascular Self
-
批准号:8138278
-
项目类别:
-
资助金额:$20.69万
-
财政年份:2011
-
负责人:JORDAN S POBER
-
依托单位:
SCID Mouse: Human Xenograft Core
-
批准号:7608570
-
项目类别:
-
资助金额:$11.28万
-
财政年份:2008
-
负责人:JORDAN S POBER
-
依托单位:
SCID Mouse : Human Xenograft Core
-
批准号:7392297
-
项目类别:
-
资助金额:$9.84万
-
财政年份:2007
-
负责人:JORDAN S POBER
-
依托单位:
Endothelial control of IFN-gamma and i-NOS in pathogenic T cells
-
批准号:7491181
-
项目类别:
-
资助金额:$42.78万
-
财政年份:2007
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:9102509
-
项目类别:
-
资助金额:$40.18万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:8657086
-
项目类别:
-
资助金额:$39.78万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:9335938
-
项目类别:
-
资助金额:$40.18万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:8529594
-
项目类别:
-
资助金额:$38.64万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
Endothelial control of IFN-gamma and i-NOS in pathogenic T cells
-
批准号:7297613
-
项目类别:
-
资助金额:$42.36万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:9759975
-
项目类别:
-
资助金额:$40.18万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
Optimizing Therapeutic Revascularization by Endothelial Cell Transplantation
-
批准号:8296172
-
项目类别:
-
资助金额:$40.48万
-
财政年份:2006
-
负责人:JORDAN S POBER
-
依托单位:
海外基金